Breaking News
Early Sale 0
⏰ Best time to enter Bitcoin? See entry/exit levels now with “Analyze chart” button on Bitcoin page
Try Now
Close

Renalytix AI (RNLXY)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.1969 +0.0081    +4.32%
19:19:50 - Delayed Data. Currency in USD
Type:  Equity
Market:  United States
  • Volume: 15,302
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 0.1894 - 0.1975
Renalytix AI Nas 0.1969 +0.0081 +4.32%

Renalytix AI Company Profile

 
Get an in-depth profile of Renalytix AI, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryHealthcare Equipment & Supplies
SectorHealthcare
Employees

-

Equity Type

ORD

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. The company’s products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. It has a license agreement with Mount Sinai Health System to develop and commercialize its products in connection with the application of artificial intelligence for the diagnosis of kidney disease. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. The company was incorporated in 2018 and is based in London, the United Kingdom.

Contact Information

Address 2 Leman Street
London, E1W 9US
United Kingdom
Phone -
Fax -

Top Executives

Name Age Since Title
Julian Huw Baines 61 2024 Executive Chairman
Erik Kristian Lium 57 2018 Independent Non-Executive Director
Joseph A. Vassalotti - 2019 Member of Clinical Advisory Board
Fergus Fleming 58 2018 CTO & Executive Director
James R. McCullough 57 2018 CEO & Director
Christopher Harwood-Bernard Mills 73 2018 Independent Non-Executive Director
Barry I. Freedman - - Member of Clinical Advisory Board
Matthew Jay Budoff - 2023 Member of Clinical Advisory Board
Eugene E. Wright - 2023 Member of Clinical Advisory Board
Javier Morales - 2023 Member of Clinical Advisory Board
Stephen Brunton - 2023 Member of Clinical Advisory Board
Ralph A. Defronzo - 2023 Member of Clinical Advisory Board
Catherine Coste 59 2023 Independent Non-Executive Director
Holly J. Mattix-Kramer - 2023 Member of Clinical Advisory Board
Robert Graham Naylor 51 2024 Non-Executive Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

RNLXY Comments

Write your thoughts about Renalytix AI
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email